NT2N Cell Transplantation and GDNF Treatment in Stroke: Linking Neurotrophic Factor Therapy and Neuroprotection

Cesario V. Borlongan, Christine E. Stahl, Guolong Yu, Lin Xu, Takao Yasuhara, Koichi Hara, Noriyuki Matsukawa, Paul R. Sanberg, Yun Wang, David C Hess

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

Accumulating scientific evidence demonstrates that diseased or aging brain cells can potentially be rescued and have their functions restored. Cell replacement therapy has emerged as the current translational research trend and in the future could provide a promising treatment intervention for various neurological disorders. One of the many nonfetal cell lines is the embryonal carcinoma cell line (NT2 cells) that are transfectable and capable of differentiating into postmitotic neuron-like cells (NT2N cells) following treatment with retinoic acid, thereby allowing this human neuronal cell line to serve as a platform for gene therapy applications for treating CNS disorders. The phenotypic characteristics of both NT2 and NT2N cells suggest the likelihood that they are an excellent platform for ex vivo gene therapy in the CNS. Additionally, exogenous treatment with glial-cell-line-derived neurotrophic factor (GDNF) has provided symptomatic relief in animal models of neurological disorders. Two neurological disorders that have been the target of GDNF therapy include stroke and Parkinson's disease (PD). Both stroke and PD lead to long-term and debilitating abnormalities in victims. Initial evidence of GDNF neuroprotective and regenerative effects was described in midbrain dopamine neurons, but subsequently extended to other CNS regions. Because of overlapping etiologies between stroke and PD, therapeutic outcomes with GDNF in either one or both diseases have contributed to the increased interest in our understanding of neuronal cell death-as well as to the development of neurotrophic-factor-based treatment strategies.

Original languageEnglish (US)
Title of host publicationCellular Transplantation
PublisherElsevier Inc.
Pages353-371
Number of pages19
ISBN (Print)9780123694157
DOIs
StatePublished - Dec 1 2007

Fingerprint

Glial Cell Line-Derived Neurotrophic Factor
Cell Transplantation
Nerve Growth Factors
Stroke
Gene therapy
Cells
Nervous System Diseases
Neurons
Parkinson Disease
Cell Line
Genetic Therapy
Cell death
Therapeutics
Tretinoin
Embryonal Carcinoma Stem Cells
Dopamine
Brain
Animals
Translational Medical Research
Aging of materials

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Borlongan, C. V., Stahl, C. E., Yu, G., Xu, L., Yasuhara, T., Hara, K., ... Hess, D. C. (2007). NT2N Cell Transplantation and GDNF Treatment in Stroke: Linking Neurotrophic Factor Therapy and Neuroprotection. In Cellular Transplantation (pp. 353-371). Elsevier Inc.. https://doi.org/10.1016/B978-012369415-7/50021-1

NT2N Cell Transplantation and GDNF Treatment in Stroke : Linking Neurotrophic Factor Therapy and Neuroprotection. / Borlongan, Cesario V.; Stahl, Christine E.; Yu, Guolong; Xu, Lin; Yasuhara, Takao; Hara, Koichi; Matsukawa, Noriyuki; Sanberg, Paul R.; Wang, Yun; Hess, David C.

Cellular Transplantation. Elsevier Inc., 2007. p. 353-371.

Research output: Chapter in Book/Report/Conference proceedingChapter

Borlongan, CV, Stahl, CE, Yu, G, Xu, L, Yasuhara, T, Hara, K, Matsukawa, N, Sanberg, PR, Wang, Y & Hess, DC 2007, NT2N Cell Transplantation and GDNF Treatment in Stroke: Linking Neurotrophic Factor Therapy and Neuroprotection. in Cellular Transplantation. Elsevier Inc., pp. 353-371. https://doi.org/10.1016/B978-012369415-7/50021-1
Borlongan CV, Stahl CE, Yu G, Xu L, Yasuhara T, Hara K et al. NT2N Cell Transplantation and GDNF Treatment in Stroke: Linking Neurotrophic Factor Therapy and Neuroprotection. In Cellular Transplantation. Elsevier Inc. 2007. p. 353-371 https://doi.org/10.1016/B978-012369415-7/50021-1
Borlongan, Cesario V. ; Stahl, Christine E. ; Yu, Guolong ; Xu, Lin ; Yasuhara, Takao ; Hara, Koichi ; Matsukawa, Noriyuki ; Sanberg, Paul R. ; Wang, Yun ; Hess, David C. / NT2N Cell Transplantation and GDNF Treatment in Stroke : Linking Neurotrophic Factor Therapy and Neuroprotection. Cellular Transplantation. Elsevier Inc., 2007. pp. 353-371
@inbook{af71015f9eba4bc08fe9b60925f07f21,
title = "NT2N Cell Transplantation and GDNF Treatment in Stroke: Linking Neurotrophic Factor Therapy and Neuroprotection",
abstract = "Accumulating scientific evidence demonstrates that diseased or aging brain cells can potentially be rescued and have their functions restored. Cell replacement therapy has emerged as the current translational research trend and in the future could provide a promising treatment intervention for various neurological disorders. One of the many nonfetal cell lines is the embryonal carcinoma cell line (NT2 cells) that are transfectable and capable of differentiating into postmitotic neuron-like cells (NT2N cells) following treatment with retinoic acid, thereby allowing this human neuronal cell line to serve as a platform for gene therapy applications for treating CNS disorders. The phenotypic characteristics of both NT2 and NT2N cells suggest the likelihood that they are an excellent platform for ex vivo gene therapy in the CNS. Additionally, exogenous treatment with glial-cell-line-derived neurotrophic factor (GDNF) has provided symptomatic relief in animal models of neurological disorders. Two neurological disorders that have been the target of GDNF therapy include stroke and Parkinson's disease (PD). Both stroke and PD lead to long-term and debilitating abnormalities in victims. Initial evidence of GDNF neuroprotective and regenerative effects was described in midbrain dopamine neurons, but subsequently extended to other CNS regions. Because of overlapping etiologies between stroke and PD, therapeutic outcomes with GDNF in either one or both diseases have contributed to the increased interest in our understanding of neuronal cell death-as well as to the development of neurotrophic-factor-based treatment strategies.",
author = "Borlongan, {Cesario V.} and Stahl, {Christine E.} and Guolong Yu and Lin Xu and Takao Yasuhara and Koichi Hara and Noriyuki Matsukawa and Sanberg, {Paul R.} and Yun Wang and Hess, {David C}",
year = "2007",
month = "12",
day = "1",
doi = "10.1016/B978-012369415-7/50021-1",
language = "English (US)",
isbn = "9780123694157",
pages = "353--371",
booktitle = "Cellular Transplantation",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - NT2N Cell Transplantation and GDNF Treatment in Stroke

T2 - Linking Neurotrophic Factor Therapy and Neuroprotection

AU - Borlongan, Cesario V.

AU - Stahl, Christine E.

AU - Yu, Guolong

AU - Xu, Lin

AU - Yasuhara, Takao

AU - Hara, Koichi

AU - Matsukawa, Noriyuki

AU - Sanberg, Paul R.

AU - Wang, Yun

AU - Hess, David C

PY - 2007/12/1

Y1 - 2007/12/1

N2 - Accumulating scientific evidence demonstrates that diseased or aging brain cells can potentially be rescued and have their functions restored. Cell replacement therapy has emerged as the current translational research trend and in the future could provide a promising treatment intervention for various neurological disorders. One of the many nonfetal cell lines is the embryonal carcinoma cell line (NT2 cells) that are transfectable and capable of differentiating into postmitotic neuron-like cells (NT2N cells) following treatment with retinoic acid, thereby allowing this human neuronal cell line to serve as a platform for gene therapy applications for treating CNS disorders. The phenotypic characteristics of both NT2 and NT2N cells suggest the likelihood that they are an excellent platform for ex vivo gene therapy in the CNS. Additionally, exogenous treatment with glial-cell-line-derived neurotrophic factor (GDNF) has provided symptomatic relief in animal models of neurological disorders. Two neurological disorders that have been the target of GDNF therapy include stroke and Parkinson's disease (PD). Both stroke and PD lead to long-term and debilitating abnormalities in victims. Initial evidence of GDNF neuroprotective and regenerative effects was described in midbrain dopamine neurons, but subsequently extended to other CNS regions. Because of overlapping etiologies between stroke and PD, therapeutic outcomes with GDNF in either one or both diseases have contributed to the increased interest in our understanding of neuronal cell death-as well as to the development of neurotrophic-factor-based treatment strategies.

AB - Accumulating scientific evidence demonstrates that diseased or aging brain cells can potentially be rescued and have their functions restored. Cell replacement therapy has emerged as the current translational research trend and in the future could provide a promising treatment intervention for various neurological disorders. One of the many nonfetal cell lines is the embryonal carcinoma cell line (NT2 cells) that are transfectable and capable of differentiating into postmitotic neuron-like cells (NT2N cells) following treatment with retinoic acid, thereby allowing this human neuronal cell line to serve as a platform for gene therapy applications for treating CNS disorders. The phenotypic characteristics of both NT2 and NT2N cells suggest the likelihood that they are an excellent platform for ex vivo gene therapy in the CNS. Additionally, exogenous treatment with glial-cell-line-derived neurotrophic factor (GDNF) has provided symptomatic relief in animal models of neurological disorders. Two neurological disorders that have been the target of GDNF therapy include stroke and Parkinson's disease (PD). Both stroke and PD lead to long-term and debilitating abnormalities in victims. Initial evidence of GDNF neuroprotective and regenerative effects was described in midbrain dopamine neurons, but subsequently extended to other CNS regions. Because of overlapping etiologies between stroke and PD, therapeutic outcomes with GDNF in either one or both diseases have contributed to the increased interest in our understanding of neuronal cell death-as well as to the development of neurotrophic-factor-based treatment strategies.

UR - http://www.scopus.com/inward/record.url?scp=79955381370&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955381370&partnerID=8YFLogxK

U2 - 10.1016/B978-012369415-7/50021-1

DO - 10.1016/B978-012369415-7/50021-1

M3 - Chapter

AN - SCOPUS:79955381370

SN - 9780123694157

SP - 353

EP - 371

BT - Cellular Transplantation

PB - Elsevier Inc.

ER -